BPA Call 36E79726A0012-36C24526N0839
Award Date 8/27/26
Potential Completion Date 9/1/26
Potential Value $38K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 5 issued a BPA call to Takeda Pharmaceuticals America, Inc. on July 31, 2026 for TAKHZYRO 150 MG with a ceiling value of $38,097.52. The call is placed under a single-award Blanket Purchase Agreement with the VA National Acquisition Center for ICLUSIG, one of Takeda's two active BPAs in the oncology pharmaceutical supply portfolio. Place of performance is Brooks, Kentucky. The ultimate completion date is August 4, 2026. TAKHZYRO (ponatinib) is a targeted...
- Veterans Integrated Service Network 5 issued a BPA call to Takeda Pharmaceuticals America, Inc. for TAKHZYRO 150 mg with a ceiling value of $38,097.52 and an award date of July 24, 2026. The call is placed against a Blanket Purchase Agreement with the VA National Acquisition Center for ICLUSIG, a targeted cancer therapy for chronic myeloid leukemia and acute lymphoblastic leukemia. Place of performance is Brooks, Kentucky. The ultimate completion date is July 28, 2026. Takeda is a large,...
- On February 5, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for rare genetic disorders. This firm fixed-price delivery order is issued under a parent Blanket Purchase Agreement established on the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB), which provides streamlined...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- On November 7, 2025, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of November 13, 2025. The award was made without a...
- On December 16, 2025, the Department of Veterans Affairs Veterans Integrated Service Network 5 awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 mg, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of December 18, 2025. The contract was awarded...
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awards Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price contract to supply TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE with a quantity of 2. The contract is issued against Takeda Pharmaceuticals America Inc.'s existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking place in Lexington, Massachusetts. No...
- Takeda Pharmaceuticals America, Inc. was awarded a delivery order by Veterans Integrated Service Network 5 (VISN 5) on November 21, 2025, for ICLUSIG 15 mg pharmaceutical product with a ceiling value of $42,592.17. This firm fixed-price delivery order, which is not designated as a small business set-aside, will be performed in Earth City, Missouri and is scheduled for completion by November 26, 2025. The award was issued under Takeda's General Services Administration (GSA) Schedule for...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order for TAKHZYRO 150MG/ML syringes. Takeda Pharmaceuticals America Inc. will deliver the syringes to a location in Lexington, Massachusetts by September 21, 2023 to fulfill requirements under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), the parent vehicle held by Takeda Pharmaceutical Company LIMITED. The funding...